Pharmacometrics Research Group, Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Department of Neurodegenerative Diseases, Center for Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
CPT Pharmacometrics Syst Pharmacol. 2024 Aug;13(8):1327-1340. doi: 10.1002/psp4.13162. Epub 2024 May 21.
The Scale for the Assessment and Rating of Ataxia (SARA) is widely used for assessing the severity and progression of genetic cerebellar ataxias. SARA is now considered a primary end point in several ataxia treatment trials, but its underlying composite item measurement model has not yet been tested. This work aimed to evaluate the composite properties of SARA and its items using item response theory (IRT) and to demonstrate its applicability across even ultra-rare genetic ataxias. Leveraging SARA subscores data from 1932 visits from 990 patients of the Autosomal Recessive Cerebellar Ataxias (ARCA) registry, we assessed the performance of SARA using IRT methodology. The item characteristics were evaluated over the ataxia severity range of the entire ataxia population as well as the assessment validity across 115 genetic ARCA subpopulations. A unidimensional IRT model was able to describe SARA item data, indicating that SARA captures one single latent variable. All items had high discrimination values (1.5-2.9) indicating the effectiveness of the SARA in differentiating between subjects with different disease statuses. Each item contributed between 7% and 28% of the total assessment informativeness. There was no evidence for differences between the 115 genetic ARCA subpopulations in SARA applicability. These results show the good discrimination ability of SARA with all of its items adding informational value. The IRT framework provides a thorough description of SARA on the item level, and facilitates its utilization as a clinical outcome assessment in upcoming longitudinal natural history or treatment trials, across a large number of ataxias, including ultra-rare ones.
用于评估遗传性小脑共济失调严重程度和进展的量表(SARA)得到广泛应用。SARA 现在被认为是几种共济失调治疗试验的主要终点,但它的基本综合项目测量模型尚未得到测试。本研究旨在使用项目反应理论(IRT)评估 SARA 及其项目的综合特性,并证明其在包括超罕见遗传性共济失调在内的多种共济失调中的适用性。利用 Autosomal Recessive Cerebellar Ataxias(ARCA)登记处的 990 名患者的 1932 次就诊的 SARA 子评分数据,我们使用 IRT 方法评估了 SARA 的性能。在整个共济失调人群的共济失调严重程度范围内以及在 115 个遗传 ARCA 亚群中的评估有效性,评估了项目特征。单维 IRT 模型能够描述 SARA 项目数据,表明 SARA 捕获了一个单一的潜在变量。所有项目的辨别力值都很高(1.5-2.9),表明 SARA 能够有效地区分不同疾病状态的受试者。每个项目对总评估信息量的贡献在 7%至 28%之间。在 SARA 的适用性方面,115 个遗传 ARCA 亚群之间没有差异的证据。这些结果表明 SARA 及其所有项目都具有良好的辨别能力,并且都增加了信息量。IRT 框架在项目级别上提供了对 SARA 的全面描述,并促进了其在未来的纵向自然史或治疗试验中作为临床结局评估的使用,涵盖了大量的共济失调,包括超罕见的共济失调。